ESLAW
Income statement / Annual
Last year (2023), Estrella Immunopharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Estrella Immunopharma, Inc.'s net income was -$7.31 M.
See Estrella Immunopharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
06/30/2024 |
12/31/2022 |
06/30/2022 |
06/30/2021 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$4.11 M
|
$0.00
|
$1.39 M
|
$457,231.00
|
| General & Administrative
Expenses |
$3.20 M
|
$0.00
|
$296,248.00
|
$276,462.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$3.20 M
|
$1.37 M
|
$296,248.00
|
$276,462.00
|
| Other Expenses |
$0.00 |
-$201,310.00 |
-$70,150.00 |
$0.00 |
| Operating Expenses |
$7.31 M |
$1.57 M |
$1.69 M |
$733,693.00 |
| Cost And Expenses |
$7.31 M |
$1.57 M |
$1.69 M |
$733,693.00 |
| Interest Income |
$0.00 |
$654,071.00 |
$1,428.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$0.00
|
$228,485.00
|
$236,558.00
|
$206,297.00
|
| EBITDA |
-$7.31 M
|
-$915,456.00
|
-$247,718.00
|
-$733,693.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$0.00
|
$654,074.00
|
$1.44 M
|
$0.00
|
| Income Before Tax |
-$7.31 M |
-$915,456.00 |
-$1.69 M |
-$733,693.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$1,625.00 |
$80,648.00 |
-$235,136.00 |
-$206,297.00 |
| Net Income |
-$7.31 M |
-$996,104.00 |
-$1.69 M |
-$733,693.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
| EPS |
-0.21 |
-0.17 |
-0.29 |
-0.0208 |
| EPS Diluted |
-0.21 |
-0.17 |
-0.29 |
-0.0208 |
| Weighted Average Shares
Out |
$35.20 M
|
$5.76 M
|
$5.85 M
|
$35.20 M
|
| Weighted Average Shares
Out Diluted |
$35.20 M
|
$5.76 M
|
$5.85 M
|
$35.20 M
|
| Link |
|
|
|
|
